ibrutinib,rituximab
abbvie,janssen
[' ibru', 'ritux', 'lymsm']
congress | #ash22 martin dreyling, md presents results from the phase iii triangle trial. the addition of ibrutinib with or without asct was associated with strong efficacy and acceptable toxicity, supporting the use of ibrutinib in younger patients with #mcl #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm